Orion Infusions (DHA:ORIONINFU) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
81 GF Score
Price BDT291.20
GF Value BDT316.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Orion Infusions's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

DHA:ORIONINFU vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orion Infusions Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Orion Infusions's Margin of Safety % (DCF Dividends Based) falls into.


DHA:ORIONINFU
81GF Score
Orion Infusions Ltd DHA:ORIONINFU
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17. GuruFocus considers Orion Infusions to be Fairly Valued.

Key valuation signals for DHA:ORIONINFU:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score

Get the complete analysis for DHA:ORIONINFU

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT291.20
Price
BDT316.17
GF Value